Controversial disease dropped from Prozac product information

Ray Moynihan

doi:10.1136/bmj.328.7436.365

Controversial disease dropped from Prozac product information

Ray Moynihan^*

^*Corresponding author for this work

Institute for Evidence-Based Healthcare

Research output: Contribution to journal › Article › Professional

11 Citations (Scopus)

Abstract

The drug manufacturer Lilly has been forced to drop one of the disorders it had previously listed for its antidepressant drug fluoxetine (Prozac), following a finding by the European drug regulator that the condition was not a well-established disease entity.

Some health researchers welcomed the regulator's decision, saying premenstrual dysphoric disorder (PMDD), which was only recently described, was an invented illness and a strong example of the medicalisation of ordinary life.

Original language	English
Pages (from-to)	365-365
Number of pages	1
Journal	BMJ (Clinical research ed.)
Volume	328
Issue number	7436
DOIs	https://doi.org/10.1136/bmj.328.7436.365
Publication status	Published - 14 Feb 2004

Access to Document

10.1136/bmj.328.7436.365

Cite this

@article{1b972afa87554b98a377ee8570ee7b9e,

title = "Controversial disease dropped from Prozac product information",

abstract = "The drug manufacturer Lilly has been forced to drop one of the disorders it had previously listed for its antidepressant drug fluoxetine (Prozac), following a finding by the European drug regulator that the condition was not a well-established disease entity. Some health researchers welcomed the regulator's decision, saying premenstrual dysphoric disorder (PMDD), which was only recently described, was an invented illness and a strong example of the medicalisation of ordinary life.",

author = "Ray Moynihan",

year = "2004",

month = feb,

day = "14",

doi = "10.1136/bmj.328.7436.365",

language = "English",

volume = "328",

pages = "365--365",

journal = "BMJ (Clinical research ed.)",

issn = "0959-535X",

publisher = "BMJ Publishing Group",

number = "7436",

}

TY - JOUR

T1 - Controversial disease dropped from Prozac product information

AU - Moynihan, Ray

PY - 2004/2/14

Y1 - 2004/2/14

N2 - The drug manufacturer Lilly has been forced to drop one of the disorders it had previously listed for its antidepressant drug fluoxetine (Prozac), following a finding by the European drug regulator that the condition was not a well-established disease entity. Some health researchers welcomed the regulator's decision, saying premenstrual dysphoric disorder (PMDD), which was only recently described, was an invented illness and a strong example of the medicalisation of ordinary life.

AB - The drug manufacturer Lilly has been forced to drop one of the disorders it had previously listed for its antidepressant drug fluoxetine (Prozac), following a finding by the European drug regulator that the condition was not a well-established disease entity. Some health researchers welcomed the regulator's decision, saying premenstrual dysphoric disorder (PMDD), which was only recently described, was an invented illness and a strong example of the medicalisation of ordinary life.

UR - https://www.scopus.com/pages/publications/12144288156

U2 - 10.1136/bmj.328.7436.365

DO - 10.1136/bmj.328.7436.365

M3 - Article

C2 - 14962861

AN - SCOPUS:12144288156

SN - 0959-535X

VL - 328

SP - 365

EP - 365

JO - BMJ (Clinical research ed.)

JF - BMJ (Clinical research ed.)

IS - 7436

ER -

Controversial disease dropped from Prozac product information

Abstract

Access to Document

Other files and links

Fingerprint

Cite this